この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2023/7/211 分で読めます
Bristol Myers Products Inc.; Withdrawal of Approval of a New Drug Application for BUFFERIN (Aspirin) Tablets
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA or Agency) is withdrawing approval of a new drug application (NDA) for BUFFERIN (aspirin) tablets. The basis for the withdrawal is that the holder of the NDA has repeatedly failed to file required annual reports for this NDA.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →